Quarterly ResultAug 11, 2026, 07:01 AM
Tango Therapeutics Vopimetostat Phase 1/2 Data Positive; Q2 Net Loss $55.3M
AI Summary
Tango Therapeutics reported positive Phase 1/2 data for vopimetostat in combination with daraxonrasib for MTAP-deleted, RAS-mutant pancreatic cancer, showing a 92% objective response rate and 90% six-month progression-free survival. The company is preparing for late-stage clinical advancement and will present data at the 2026 ESMO Congress. Financially, Tango reported a Q2 2026 net loss of $55.3 million and held $1.0 billion in cash, cash equivalents, and marketable securities as of June 30, 2026. Key appointments include Fatma Ocak as Chief Commercialization Officer and Robert Azelby as Chairman of the Board.
Key Highlights
- Vopimetostat + daraxonrasib achieved 92% objective response rate in pancreatic cancer.
- Combination showed 90% six-month progression-free survival rate in Phase 1/2.
- Cash, cash equivalents, and marketable securities totaled $1.0 billion as of June 30, 2026.
- Q2 2026 net loss was $55.3 million, or $0.37 per share.
- Q2 2026 R&D expenses increased to $37.2 million from $32.8 million year-over-year.
- Fatma Ocak appointed Chief Commercialization Officer, effective August 17, 2026.
- Robert Azelby appointed Chairman of the Board of Directors on August 6, 2026.
Price Impact
More from TNGX